Mabylon AG Secures Critical Funding for Innovative Therapies
Mabylon AG, a leading name in the biotechnology industry, which is focused on human-derived antibodies, has recently made headlines by securing an impressive three research grants totaling over CHF 1.3 million. This funding is earmarked for their projects targeting amyotrophic lateral sclerosis (ALS) and therapies that focus on inflammasomes. These significant developments underscore their commitment to advancing medical research and treatment options.
Focus on Amyotrophic Lateral Sclerosis
Among the substantial grants are notable contributions from organizations such as the Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association. Specifically, the funding is aimed at furthering the development of TDP-43 intrabodies, which are intended to help restore normal TDP-43 functions in ALS patients. There’s a pressing need for effective treatments since TDP-43 aggregates are a key factor in the progression of ALS.
The Importance of TDP-43
TDP-43 is recognized as a critical target in combating ALS, influencing both the familial and sporadic types of the disease. Kuldip Dave, Ph.D., the Senior Vice President of Research at the ALS Association, expressed optimism about how this funding can advance preclinical development efforts. He emphasized that making swift progress toward viable treatment options is crucial for managing ALS effectively.
Advances in Inflammatory Bowel Disease Treatment
In addition to its work on ALS, Mabylon is directing CHF 0.8 million from Innosuisse toward its ambitious MY012 program. This innovative antiviral therapy specifically targets inflammatory bowel disease (IBD) and aims to improve both safety and efficacy for patient treatments.
Innovative Approaches to Safe Treatments
Mabylon’s approach is to identify naturally occurring antibodies from large patient populations or immunized animals. This cutting-edge strategy lays the groundwork for discovering promising antibody candidates for ALS and IBD. Niccolò Pengo, PhD, who serves as Mabylon’s Chief Scientific Officer (CSO), noted that these grants validate their research efforts and highlight the therapeutic potential of their findings. The funding enables them to accelerate their research programs and will assist in future fundraising initiatives.
Vision for the Future
Alcide Barberis, PhD, CEO of Mabylon, conveyed his sincere appreciation for the grants, which will help advance their mission to achieve preclinical proof-of-concept. Their aim is to cultivate partnerships with biopharmaceutical companies or potentially establish a dedicated spin-off to attract investments. With a sharp focus on their innovative anti-allergen antibody candidates, the company is well-positioned for future growth.
Recent Collaborations and Developments
In the last few months, Mabylon has made significant progress with its anti-allergen therapies, especially with a multi-specific anti-allergen antibody currently undergoing Investigative New Drug (IND) studies. This important project is designed to deliver much-needed treatments for peanut allergies. Furthermore, Mabylon has joined forces with Pfizer through the Pfizer Ignite program to advance its allergy treatment ambitions.
About Mabylon AG
Mabylon AG is a Swiss biotechnology firm committed to harnessing the therapeutic potential of naturally occurring human antibodies to tackle allergies, neurodegenerative diseases, and inflammatory conditions. By concentrating on antibodies derived from allergic patients, Mabylon enhances the understanding of allergenic epitopes and their role in disease progression.
Frequently Asked Questions
What grants has Mabylon AG received?
Mabylon AG has received over CHF 1.3 million in research grants focused on ALS and inflammatory diseases.
How is the funding benefiting ALS research?
The funding is being used to develop TDP-43 intrabodies, which aim to restore normal TDP-43 function in ALS patients.
What is the MY012 program?
The MY012 program focuses on inflammatory bowel disease, utilizing a proprietary antibody therapy designed to enhance safety and effectiveness.
What collaborations does Mabylon have?
Mabylon has partnered with Pfizer for its allergy program through the Pfizer Ignite initiative.
What is Mabylon AG's primary focus?
Mabylon AG specializes in leveraging naturally occurring human antibodies to innovate treatments for allergies, neurodegenerative diseases, and inflammatory conditions.
